Zobrazeno 1 - 10
of 17
pro vyhledávání: '"Christoph A. von Klot"'
Autor:
Olga Katzendorn, Inga Peters, Natalia Dubrowinskaja, Hossein Tezval, Pouriya Faraj Tabrizi, Christoph A. von Klot, Jörg Hennenlotter, Marcel Lafos, Markus A. Kuczyk, Jürgen Serth
Publikováno v:
BMC Cancer, Vol 21, Iss 1, Pp 1-11 (2021)
Abstract Background DNA methylation is frequently observed in the development and progression of many human tumors as well as renal cell cancer (RCC). Tumor Associated Calcium Signal Transducer 2 (TACSTD2) participates in cell cycle progression throu
Externí odkaz:
https://doaj.org/article/177404d0eda24c7eb89204fddace0e08
Autor:
Margarete Teresa Walach, Frank Schiefelbein, Andreas Schneller, Georg Schoen, Christoph A.J. von Klot, Olga Katzendorn, Julia Mühlbauer, Philipp Nuhn, Maximilian Christian Kriegmair, Nina Natascha Harke
Publikováno v:
Urologia Internationalis. 107:126-133
Introduction: To assess influencing factors on perinephric toxic fat (high Mayo Adhesive Probability [MAP] score) and the impact of high MAP scores on surgical complexity, perioperative outcome, and surgical approach in patients with localized renal
Autor:
Nina N. Harke, Frank Schiefelbein, Andreas Schneller, Georg Schoen, Olga Katzendorn, Christoph A.J. von Klot, Julia K. Mühlbauer, Philipp Nuhn, Maximilian C. Kriegmair, Margarete T. Walach
Publikováno v:
Journal of Urology. 207
Publikováno v:
Therapeutic Advances in Urology, Vol 7 (2015)
Enzalutamide is an oral androgen receptor inhibitor that targets multiple steps in the androgen receptor signaling pathway. In the randomized phase III AFFIRM study, significant improvements in survival versus placebo were observed when enzalutamide
Externí odkaz:
https://doaj.org/article/cf94f348ffdc43e28f31359957f4f42d
Autor:
Bennet Hensen, Mario W. Kramer, Axel S. Merseburger, Marie C. Hupe, Inga Peters, Alexander Fürschke, Christoph-A. von Klot, Julian P. Struck, Markus A. Kuczyk, Christian Fuhrmann, Philipp Ivanyi
Publikováno v:
Frontiers in Oncology
Frontiers in Oncology, Vol 10 (2020)
Frontiers in Oncology, Vol 10 (2020)
Background: The introduction of checkpoint inhibitors is a long-awaited new option for a urothelial cancer with a poor prognosis. Apart from clinical studies, the data on real world experience is scarce. Methods: Patients for monotherapy with either
Autor:
Tobias L. Ross, Christoph-A. von Klot, Stefan Nordlohne, Hans-Jürgen Wester, Hans Christiansen, Thorsten Derlin, Frank M. Bengel, Jan M Sohns, Christoph Henkenberens, Sebastian Schmuck
Publikováno v:
European Journal of Nuclear Medicine and Molecular Imaging. 44:960-968
The aim of this study was to assess the value of dual-time point imaging in PET/CT for detection of biochemically recurrent or persistent prostate cancer, using the prostate-specific membrane antigen (PSMA) ligand [68Ga]PSMA I&T. 240 patients who und
Autor:
Jürgen Serth, Markus A. Kuczyk, Natalia Dubrowinskaja, Arnulf Stenzl, Christoph‑Alexander von Klot, Inga Peters, Axel S. Merseburger, Jörg Hennenlotter
Publikováno v:
Oncology Letters.
Rho GDP dissociation inhibitor-β (ARHGDIB) is an important mediator of cell signaling. The expression of ARHGDIB is associated with tumor growth and metastasis in a variety of non-genitourinary cancers; however, the role of ARHGDIB in renal cell car
Autor:
Thorsten, Derlin, Sebastian, Schmuck, Cathleen, Juhl, Johanna, Zörgiebel, Sophie M, Schneefeld, Almut C A, Walte, Katja, Hueper, Christoph A, von Klot, Christoph, Henkenberens, Hans, Christiansen, James T, Thackeray, Tobias L, Ross, Frank M, Bengel
Publikováno v:
European journal of nuclear medicine and molecular imaging. 45(6)
[Consecutive patients (n=99) referred for evaluation of biochemical relapse of prostate cancer by [At least one lesion suggestive of recurrent or metastatic prostate cancer was identified on PET images in 52 patients (52.5%). Detection rates of [In t
Autor:
Christoph, Henkenberens, Thorsten, Derlin, Frank M, Bengel, Tobias L, Ross, Hans-Jürgen, Wester, Katja, Hueper, Markus A, Kuczyk, Hans, Christiansen, Christoph A, von Klot
Publikováno v:
Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al]. 194(4)
To evaluate the patterns of relapse and impact on the intended treatment when usingIn all, 39 patients with biochemical recurrence after RP who had no primary indication for adjuvant RT due to the absence of biologically unfavorable disease (e.g., ex
Autor:
Sebastian, Schmuck, Christoph A, von Klot, Christoph, Henkenberens, Jan M, Sohns, Hans, Christiansen, Hans-Jürgen, Wester, Tobias L, Ross, Frank M, Bengel, Thorsten, Derlin
Publikováno v:
Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 58(12)
A quantitative imaging biomarker is desirable to provide a comprehensive measure of whole-body tumor burden in patients with metastatic prostate cancer, and to standardize the evaluation of treatment-related changes. Therefore, we evaluated whether p